- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.45 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 2 x MG: MAGNESIUM ION(Non-covalent)
MG.2: 2 residues within 4Å:- Chain A: D.137
- Ligands: ZN.1
6 PLIP interactions:1 interactions with chain A, 5 Ligand-Water interactions- Metal complexes: A:D.137, H2O.2, H2O.2, H2O.3, H2O.4, H2O.7
MG.20: 2 residues within 4Å:- Chain B: D.137
- Ligands: ZN.21
6 PLIP interactions:1 interactions with chain B, 5 Ligand-Water interactions- Metal complexes: B:D.137, H2O.9, H2O.10, H2O.11, H2O.11, H2O.13
- 2 x EQC: Arctigenin(Non-covalent)
EQC.3: 12 residues within 4Å:- Chain A: Y.95, H.96, M.209, N.257, W.268, T.269, I.272, M.293, Q.305, F.308, I.312
- Ligands: EDO.4
4 PLIP interactions:4 interactions with chain A- Hydrophobic interactions: A:F.308
- Hydrogen bonds: A:Q.305
- Salt bridges: A:H.96
- pi-Stacking: A:F.308
EQC.22: 13 residues within 4Å:- Chain B: Y.95, H.96, M.209, N.257, Y.265, W.268, T.269, I.272, M.293, Q.305, F.308, I.312
- Ligands: EDO.29
4 PLIP interactions:4 interactions with chain B- Hydrophobic interactions: B:F.308
- Hydrogen bonds: B:Q.305
- Salt bridges: B:H.96
- pi-Stacking: B:F.308
- 26 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.4: 6 residues within 4Å:- Chain A: S.144, F.276, S.291, P.292, C.294
- Ligands: EQC.3
Ligand excluded by PLIPEDO.5: 4 residues within 4Å:- Chain A: H.90, D.92, V.93, P.141
Ligand excluded by PLIPEDO.6: 5 residues within 4Å:- Chain A: N.51, A.91, N.97, N.98, I.99
Ligand excluded by PLIPEDO.7: 3 residues within 4Å:- Chain A: D.337, N.338, W.341
Ligand excluded by PLIPEDO.8: 5 residues within 4Å:- Chain A: K.198, I.201, D.202
- Chain B: N.160, S.162
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain A: T.122, L.124, E.125, S.195, M.199
Ligand excluded by PLIPEDO.10: 6 residues within 4Å:- Chain A: T.70, F.71, K.72, N.187, L.188, Q.192
Ligand excluded by PLIPEDO.11: 4 residues within 4Å:- Chain A: F.174, F.185, R.193, R.197
Ligand excluded by PLIPEDO.12: 2 residues within 4Å:- Chain A: P.261, Q.263
Ligand excluded by PLIPEDO.13: 7 residues within 4Å:- Chain A: L.112, L.117, E.118, A.119, V.120, F.121, I.126
Ligand excluded by PLIPEDO.14: 4 residues within 4Å:- Chain A: Q.194, R.197
- Chain B: I.149, D.161
Ligand excluded by PLIPEDO.15: 7 residues within 4Å:- Chain A: M.222, T.225, K.226, K.227, L.235, L.236, D.241
Ligand excluded by PLIPEDO.16: 5 residues within 4Å:- Chain A: R.266, E.302, W.341, Y.342
- Ligands: EDO.17
Ligand excluded by PLIPEDO.17: 6 residues within 4Å:- Chain A: R.266, T.269, D.270, V.301, Y.342
- Ligands: EDO.16
Ligand excluded by PLIPEDO.18: 5 residues within 4Å:- Chain A: I.309, D.310, H.314, E.336, R.339
Ligand excluded by PLIPEDO.19: 2 residues within 4Å:- Chain A: P.115, G.232
Ligand excluded by PLIPEDO.23: 5 residues within 4Å:- Chain B: S.144, F.276, S.291, P.292
- Ligands: EDO.29
Ligand excluded by PLIPEDO.24: 5 residues within 4Å:- Chain B: L.235, L.236, D.237, N.238, D.241
Ligand excluded by PLIPEDO.25: 5 residues within 4Å:- Chain A: N.160, S.162
- Chain B: K.198, I.201, D.202
Ligand excluded by PLIPEDO.26: 6 residues within 4Å:- Chain B: L.111, T.114, W.320, D.327, A.328, I.331
Ligand excluded by PLIPEDO.27: 5 residues within 4Å:- Chain B: F.174, L.177, F.185, R.193, R.197
Ligand excluded by PLIPEDO.28: 6 residues within 4Å:- Chain B: N.51, E.86, D.87, Y.89, A.91, N.98
Ligand excluded by PLIPEDO.29: 10 residues within 4Å:- Chain B: H.96, H.140, G.142, V.143, S.144, E.275, F.276, Q.279
- Ligands: EQC.22, EDO.23
Ligand excluded by PLIPEDO.30: 2 residues within 4Å:- Chain A: M.158
- Chain B: A.171
Ligand excluded by PLIPEDO.31: 4 residues within 4Å:- Chain B: H.90, D.92, V.93, P.141
Ligand excluded by PLIPEDO.32: 5 residues within 4Å:- Chain B: R.266, E.302, W.341, Y.342, T.345
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Li, H. et al., Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation. J Adv Res (2021)
- Release Date
- 2021-04-14
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4D: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.45 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 2 x MG: MAGNESIUM ION(Non-covalent)
- 2 x EQC: Arctigenin(Non-covalent)
- 26 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Li, H. et al., Identification of phosphodiesterase-4 as the therapeutic target of arctigenin in alleviating psoriatic skin inflammation. J Adv Res (2021)
- Release Date
- 2021-04-14
- Peptides
- cAMP-specific 3',5'-cyclic phosphodiesterase 4D: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B